NUR 354 | PHARMACOLOGY II
EXAM 2
COMPREHENSIVE REVIEW
Full Practice Questions, Correct Answers & Detailed Nursing Rationales
100 original multiple-choice questions | Focused cardiac and nephrology medication review | September
preparation edition
WHAT YOU RECEIVE BASED ON HOW TO USE
100 original questions + answer key + Uploaded 11-page NUR 354 Exam 2 Independent self-test, clinical judgment
rationales cardiac / nephrology study guide review and medication safety practice
Source-aligned expanded edition
This updated PDF incorporates a source-mapped review based on the attached 11-page study guide. It then provides
the complete 100-question practice examination, the answer key, and question-by-question rationales. The notes
are treated as a study outline rather than as an official college examination blueprint.
Clinical safety: The original study notes include simplified teaching statements. Where necessary, this edition explicitly labels
clarifications from current clinical guidelines and drug labeling. No passing score is verified or promised. This PDF is for educational
purposes, not direct clinical orders.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 1
, SOURCE ALIGNMENT / ELEVEN-PAGE REFERENCE
Your uploaded study guide: topic map
The uploaded PDF is an 11-page outline titled NUR 354 Exam 2 Comprehensive Study Guide - Cardiac & Nephrology
Pharmacology Review. The table below preserves its progression while pointing to matching study sections in the
examination.
GUIDE MAIN TOPICS IN THE UPLOADED NOTES RELATED EXAM QUESTIONS
PAGE(S)
1-2 Heart-disease risk factors; stable and unstable angina; nitrate routes; beta Q76-89 (nitrates, angina, rate
blockers; ranolazine control)
3 Acute coronary syndrome; MI recognition; troponin; reperfusion; aspirin, Q90-100 (ACS and emergency
heparin and fibrinolytics priorities)
4-5 Nephron functions; loop and thiazide diuretics; spironolactone; mannitol; Q1-25 (renal and diuretic
ADH; acetazolamide pharmacology)
6-8 Hypertension frameworks; ACE inhibitors and ARBs; thiazides; Q26-50 and parts of Q51-75
dihydropyridine CCBs
9-11 Non-dihydropyridine CCBs; hydralazine; nitroprusside; clonidine; aliskiren; Q51-75 (other BP drug classes)
alpha and beta blockers
Exam organization
UNIT QUESTION RANGE WHAT TO MASTER
1. Renal and diuretics 1-25 Nephron sites; potassium, sodium, fluid and renal monitoring
2. RAAS and blood pressure 26-50 ACE inhibitors, ARBs, aliskiren; BP categories; safety
3. Other antihypertensives 51-75 Beta blockers, CCBs, alpha-1 blockers, clonidine and
vasodilators
4. Angina and ACS 76-100 Nitrates, ranolazine, myocardial infarction and emergency care
Important: These numbered question ranges describe the original practice set in this resource, not question numbers from the
uploaded guide. Institutional Exam 2 coverage and item counts may differ.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 2
, READ BEFORE THE PRACTICE EXAM
Clinical accuracy and 2026 safety clarifications
The uploaded material is valuable for its topic outline. The following distinctions are explicitly added because
simplifying them can create unsafe clinical interpretations. These clarifications are based on the 2025 AHA/ACC ACS
and hypertension guidelines and U.S. drug labeling, rather than on the uploaded study guide alone.
TOPIC / SOURCE IMPORTANT CLARIFICATION
EMPHASIS
Chest pain and nitroglycerin New, severe, atypical or continuing ischemic chest pain requires urgent emergency evaluation.
Do not delay calling emergency services solely to complete three nitroglycerin doses. For
patients with prescribed nitroglycerin, follow their individualized emergency action plan.
NSTEMI and ECG findings An NSTEMI can show ST depression, T-wave changes or a nondiagnostic ECG. ECG findings,
clinical presentation and serial high-sensitivity troponin inform diagnosis; lack of ST elevation
does not mean a normal ECG.
Routine oxygen after MI Oxygen is administered when clinically indicated for hypoxemia or respiratory compromise;
automatic oxygen for every ACS patient with adequate saturation is not recommended.
Blood pressure medication 2025 U.S. guidance recommends first-line thiazide-type diuretics, long-acting dihydropyridine
selection CCBs, ACE inhibitors or ARBs in appropriate adults. Initial combination therapy is favored in stage
2 hypertension; not every patient requires two agents.
Pregnancy and BP medicines ACE inhibitors, ARBs and direct renin inhibitors should be avoided during pregnancy. Appropriate
alternatives require individualized obstetric management; do not assume that every
antihypertensive medication is contraindicated.
Sources: 2025 AHA/ACC acute coronary syndrome guideline; 2025 adult high-blood-pressure guideline; DailyMed nitroglycerin
labeling. Reference URLs appear in the source notes at the end of this supplement.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 3
, UPLOAD-BASED UNIT A / PAGES 1-3
High-yield review | Cardiac & angina pharmacology
Risk reduction and forms of angina
The source opens with modifiable risk factors: nutrition quality, physical activity, tobacco avoidance, weight
management, glucose control, lipid management, blood-pressure control and sleep. Stable angina is typically
predictable with exertion or stress and improves with rest or prescribed antianginal treatment. Unstable angina can
occur at rest, be new or worsen; it requires urgent assessment for acute coronary syndrome. Vasospastic angina
reflects transient coronary spasm and is frequently treated with calcium channel blockers and nitrates.
Nitrates, beta blockers and ranolazine
MEDICATION MAIN EFFECT PRIORITY NURSING CHECK
Nitroglycerin (SL, transdermal, Vasodilation reduces cardiac workload; SL is Assess blood pressure, pain, dizziness and
IV) used for rapid relief of prescribed angina recent PDE-5 inhibitor use; patches are
preventive, not rescue therapy.
Beta blockers (metoprolol, Reduce beta-adrenergic stimulation, typically Assess pulse/BP, heart block, heart failure
propranolol, carvedilol) lowering heart rate and myocardial oxygen status and potential bronchospasm with
demand nonselective agents.
Ranolazine Reduces chronic angina symptoms partly Not for acute rescue; review QT concerns and
through late sodium-current effects clinically significant drug interactions.
Three practical comparisons
• Acute relief versus prevention: Sublingual nitroglycerin may relieve a prescribed episode of angina; extended-release nitrates,
transdermal preparations and ranolazine are used for ongoing prevention.
• Expected versus dangerous nitrate reactions: Headache and lightheadedness may occur, but profound hypotension or syncope
requires urgent reassessment.
• Beta blockade: A decreasing pulse may reflect drug action, but symptomatic bradycardia, hypotension or a new conduction
problem requires withholding or clarifying according to the order and protocol.
Source trace: uploaded guide pages 1-2. Contemporary safety clarification: nitroglycerin and beta blockers must be assessed in the
context of the individual patient and medication order.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 4
EXAM 2
COMPREHENSIVE REVIEW
Full Practice Questions, Correct Answers & Detailed Nursing Rationales
100 original multiple-choice questions | Focused cardiac and nephrology medication review | September
preparation edition
WHAT YOU RECEIVE BASED ON HOW TO USE
100 original questions + answer key + Uploaded 11-page NUR 354 Exam 2 Independent self-test, clinical judgment
rationales cardiac / nephrology study guide review and medication safety practice
Source-aligned expanded edition
This updated PDF incorporates a source-mapped review based on the attached 11-page study guide. It then provides
the complete 100-question practice examination, the answer key, and question-by-question rationales. The notes
are treated as a study outline rather than as an official college examination blueprint.
Clinical safety: The original study notes include simplified teaching statements. Where necessary, this edition explicitly labels
clarifications from current clinical guidelines and drug labeling. No passing score is verified or promised. This PDF is for educational
purposes, not direct clinical orders.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 1
, SOURCE ALIGNMENT / ELEVEN-PAGE REFERENCE
Your uploaded study guide: topic map
The uploaded PDF is an 11-page outline titled NUR 354 Exam 2 Comprehensive Study Guide - Cardiac & Nephrology
Pharmacology Review. The table below preserves its progression while pointing to matching study sections in the
examination.
GUIDE MAIN TOPICS IN THE UPLOADED NOTES RELATED EXAM QUESTIONS
PAGE(S)
1-2 Heart-disease risk factors; stable and unstable angina; nitrate routes; beta Q76-89 (nitrates, angina, rate
blockers; ranolazine control)
3 Acute coronary syndrome; MI recognition; troponin; reperfusion; aspirin, Q90-100 (ACS and emergency
heparin and fibrinolytics priorities)
4-5 Nephron functions; loop and thiazide diuretics; spironolactone; mannitol; Q1-25 (renal and diuretic
ADH; acetazolamide pharmacology)
6-8 Hypertension frameworks; ACE inhibitors and ARBs; thiazides; Q26-50 and parts of Q51-75
dihydropyridine CCBs
9-11 Non-dihydropyridine CCBs; hydralazine; nitroprusside; clonidine; aliskiren; Q51-75 (other BP drug classes)
alpha and beta blockers
Exam organization
UNIT QUESTION RANGE WHAT TO MASTER
1. Renal and diuretics 1-25 Nephron sites; potassium, sodium, fluid and renal monitoring
2. RAAS and blood pressure 26-50 ACE inhibitors, ARBs, aliskiren; BP categories; safety
3. Other antihypertensives 51-75 Beta blockers, CCBs, alpha-1 blockers, clonidine and
vasodilators
4. Angina and ACS 76-100 Nitrates, ranolazine, myocardial infarction and emergency care
Important: These numbered question ranges describe the original practice set in this resource, not question numbers from the
uploaded guide. Institutional Exam 2 coverage and item counts may differ.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 2
, READ BEFORE THE PRACTICE EXAM
Clinical accuracy and 2026 safety clarifications
The uploaded material is valuable for its topic outline. The following distinctions are explicitly added because
simplifying them can create unsafe clinical interpretations. These clarifications are based on the 2025 AHA/ACC ACS
and hypertension guidelines and U.S. drug labeling, rather than on the uploaded study guide alone.
TOPIC / SOURCE IMPORTANT CLARIFICATION
EMPHASIS
Chest pain and nitroglycerin New, severe, atypical or continuing ischemic chest pain requires urgent emergency evaluation.
Do not delay calling emergency services solely to complete three nitroglycerin doses. For
patients with prescribed nitroglycerin, follow their individualized emergency action plan.
NSTEMI and ECG findings An NSTEMI can show ST depression, T-wave changes or a nondiagnostic ECG. ECG findings,
clinical presentation and serial high-sensitivity troponin inform diagnosis; lack of ST elevation
does not mean a normal ECG.
Routine oxygen after MI Oxygen is administered when clinically indicated for hypoxemia or respiratory compromise;
automatic oxygen for every ACS patient with adequate saturation is not recommended.
Blood pressure medication 2025 U.S. guidance recommends first-line thiazide-type diuretics, long-acting dihydropyridine
selection CCBs, ACE inhibitors or ARBs in appropriate adults. Initial combination therapy is favored in stage
2 hypertension; not every patient requires two agents.
Pregnancy and BP medicines ACE inhibitors, ARBs and direct renin inhibitors should be avoided during pregnancy. Appropriate
alternatives require individualized obstetric management; do not assume that every
antihypertensive medication is contraindicated.
Sources: 2025 AHA/ACC acute coronary syndrome guideline; 2025 adult high-blood-pressure guideline; DailyMed nitroglycerin
labeling. Reference URLs appear in the source notes at the end of this supplement.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 3
, UPLOAD-BASED UNIT A / PAGES 1-3
High-yield review | Cardiac & angina pharmacology
Risk reduction and forms of angina
The source opens with modifiable risk factors: nutrition quality, physical activity, tobacco avoidance, weight
management, glucose control, lipid management, blood-pressure control and sleep. Stable angina is typically
predictable with exertion or stress and improves with rest or prescribed antianginal treatment. Unstable angina can
occur at rest, be new or worsen; it requires urgent assessment for acute coronary syndrome. Vasospastic angina
reflects transient coronary spasm and is frequently treated with calcium channel blockers and nitrates.
Nitrates, beta blockers and ranolazine
MEDICATION MAIN EFFECT PRIORITY NURSING CHECK
Nitroglycerin (SL, transdermal, Vasodilation reduces cardiac workload; SL is Assess blood pressure, pain, dizziness and
IV) used for rapid relief of prescribed angina recent PDE-5 inhibitor use; patches are
preventive, not rescue therapy.
Beta blockers (metoprolol, Reduce beta-adrenergic stimulation, typically Assess pulse/BP, heart block, heart failure
propranolol, carvedilol) lowering heart rate and myocardial oxygen status and potential bronchospasm with
demand nonselective agents.
Ranolazine Reduces chronic angina symptoms partly Not for acute rescue; review QT concerns and
through late sodium-current effects clinically significant drug interactions.
Three practical comparisons
• Acute relief versus prevention: Sublingual nitroglycerin may relieve a prescribed episode of angina; extended-release nitrates,
transdermal preparations and ranolazine are used for ongoing prevention.
• Expected versus dangerous nitrate reactions: Headache and lightheadedness may occur, but profound hypotension or syncope
requires urgent reassessment.
• Beta blockade: A decreasing pulse may reflect drug action, but symptomatic bradycardia, hypotension or a new conduction
problem requires withholding or clarifying according to the order and protocol.
Source trace: uploaded guide pages 1-2. Contemporary safety clarification: nitroglycerin and beta blockers must be assessed in the
context of the individual patient and medication order.
NUR 354 • EXAM 2 • SOURCE-ALIGNED 2026/2027 EDITION STUDY COMPANION • 4
